Not admitted · Not a forecast

“This deal tells me that they both believe that the science behind their lead assets is strong and the ability to bring them to market successfully seemed so promising they had to do this deal—not just for those assets, but for the whole team. This speaks to both the science and the team at Atai-Beckley, and provides much needed hope for those suffering with depression. It's a vote for both psychedelic medicine and the market value of bringing this healing to scale.”